Brief: Herantis Pharma Announces Approval Of Clinical Trial Application For Phase 1 Study

Herantis Pharma Oyj

20/02/2023 11:06

Feb 20 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATION (CTA) FOR
A
PHASE 1 STUDY FOR HER-096
    * WILL INITIATE PHASE 1 STUDY WITH AIM TO DEMONSTRATE
EVIDENCE OF
HER-096 SAFETY AND BLOOD-BRAIN PENETRATION IN HUMANS
    * IS PLEASED TO ANNOUNCE THAT FINNISH MEDICINES AGENCY,
FIMEA AND
ETHICS COMMITTEE HAVE APPROVED CLINICAL TRIAL APPLICATION (CTA)
SUBMITTED IN DECEMBER 2022
    * PHASE 1 STUDY WILL BE CONDUCTED IN FINLAND

Source text for Eikon:  ID:nWkr6yt5vN 
Further company coverage:  HRTIS.HE 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))